AAPL   364.11 (+0.00%)
MSFT   206.26 (+0.76%)
FB   233.42 (-1.74%)
GOOGL   1,469.93 (+1.94%)
AMZN   2,890.30 (+0.40%)
NVDA   384.49 (+0.86%)
BABA   223.60 (+3.54%)
MU   49.83 (+0.26%)
GE   6.82 (+1.19%)
TSLA   1,208.66 (+7.95%)
AMD   52.34 (-0.46%)
T   30.08 (+0.57%)
ACB   12.27 (+0.00%)
F   6.05 (+1.17%)
BAC   23.29 (+0.13%)
NFLX   476.89 (-1.80%)
BA   180.81 (+0.27%)
AAPL   364.11 (+0.00%)
MSFT   206.26 (+0.76%)
FB   233.42 (-1.74%)
GOOGL   1,469.93 (+1.94%)
AMZN   2,890.30 (+0.40%)
NVDA   384.49 (+0.86%)
BABA   223.60 (+3.54%)
MU   49.83 (+0.26%)
GE   6.82 (+1.19%)
TSLA   1,208.66 (+7.95%)
AMD   52.34 (-0.46%)
T   30.08 (+0.57%)
ACB   12.27 (+0.00%)
F   6.05 (+1.17%)
BAC   23.29 (+0.13%)
NFLX   476.89 (-1.80%)
BA   180.81 (+0.27%)
AAPL   364.11 (+0.00%)
MSFT   206.26 (+0.76%)
FB   233.42 (-1.74%)
GOOGL   1,469.93 (+1.94%)
AMZN   2,890.30 (+0.40%)
NVDA   384.49 (+0.86%)
BABA   223.60 (+3.54%)
MU   49.83 (+0.26%)
GE   6.82 (+1.19%)
TSLA   1,208.66 (+7.95%)
AMD   52.34 (-0.46%)
T   30.08 (+0.57%)
ACB   12.27 (+0.00%)
F   6.05 (+1.17%)
BAC   23.29 (+0.13%)
NFLX   476.89 (-1.80%)
BA   180.81 (+0.27%)
AAPL   364.11 (+0.00%)
MSFT   206.26 (+0.76%)
FB   233.42 (-1.74%)
GOOGL   1,469.93 (+1.94%)
AMZN   2,890.30 (+0.40%)
NVDA   384.49 (+0.86%)
BABA   223.60 (+3.54%)
MU   49.83 (+0.26%)
GE   6.82 (+1.19%)
TSLA   1,208.66 (+7.95%)
AMD   52.34 (-0.46%)
T   30.08 (+0.57%)
ACB   12.27 (+0.00%)
F   6.05 (+1.17%)
BAC   23.29 (+0.13%)
NFLX   476.89 (-1.80%)
BA   180.81 (+0.27%)
Log in

OTCMKTS:CPHRFCipher Pharmaceuticals Stock Price, Forecast & News

$0.90
0.00 (0.00 %)
(As of 07/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.90
Now: $0.90
$0.90
50-Day Range
$0.87
MA: $0.89
$0.95
52-Week Range
$0.30
Now: $0.90
$1.22
VolumeN/A
Average Volume4,553 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CPHRF
Previous SymbolNASDAQ:CPHR
CUSIPN/A
CIKN/A
Phone+1-905-6025840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CPHRF News and Ratings via Email

Sign-up to receive the latest news and ratings for CPHRF and its competitors with MarketBeat's FREE daily newsletter.

Cipher Pharmaceuticals (OTCMKTS:CPHRF) Frequently Asked Questions

How has Cipher Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cipher Pharmaceuticals' stock was trading at $0.6097 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CPHRF shares have increased by 47.6% and is now trading at $0.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cipher Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cipher Pharmaceuticals.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (OTCMKTS:CPHRF) issued its quarterly earnings results on Thursday, May, 5th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $10.87 million. View Cipher Pharmaceuticals' earnings history.

What price target have analysts set for CPHRF?

2 Wall Street analysts have issued 12-month price targets for Cipher Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Cipher Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 344.4% from the stock's current price. View analysts' price targets for Cipher Pharmaceuticals.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

Media coverage about CPHRF stock has been trending very negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cipher Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the following people:
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Chris Watters, VP of Corp. Devel.
  • Dr. Diane Gajewczyk, VP of Scientific & Medical Affairs
  • Mr. Norman Evans, Consultant (Age 64)

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPHRF stock can currently be purchased for approximately $0.90.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is www.cipherpharma.com.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.